Daniela Bumbaca Yadav
Overview
Explore the profile of Daniela Bumbaca Yadav including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Phillips G, Guo J, Kiefer J, Proctor W, Bumbaca Yadav D, Dybdal N, et al.
Breast Cancer Res Treat
. 2021 Oct;
191(2):303-317.
PMID: 34708303
Purpose: Assessment of non-clinical safety signals relies on understanding species selectivity of antibodies. This is particularly important with antibody-drug conjugates, where it is key to determine target-dependent versus target-independent toxicity....
2.
Bloomingdale P, Bakshi S, Maass C, van Maanen E, Pichardo-Almarza C, Bumbaca Yadav D, et al.
J Pharmacokinet Pharmacodyn
. 2021 Aug;
48(6):861-871.
PMID: 34378151
There are several antibody therapeutics in preclinical and clinical development, industry-wide, for the treatment of central nervous system (CNS) disorders. Due to the limited permeability of antibodies across brain barriers,...
3.
Ayalon G, Lee S, Adolfsson O, Foo-Atkins C, Atwal J, Blendstrup M, et al.
Sci Transl Med
. 2021 May;
13(593).
PMID: 33980574
Tau has become an attractive alternative target for passive immunotherapy efforts for Alzheimer's disease (AD). The anatomical distribution and extent of tau pathology correlate with disease course and severity better...
4.
Bantseev V, Horvath J, Barteselli G, Ranade S, Maia M, Bumbaca Yadav D, et al.
Toxicol Pathol
. 2020 Nov;
49(3):663-672.
PMID: 33205714
The Port Delivery System with ranibizumab (PDS) is an investigational drug delivery system designed to provide continuous intravitreal release of ranibizumab for extended durations. The PDS consists of a permanent,...
5.
Bumbaca Yadav D, Reyes 2nd A, Gupta P, Vernes J, Meng Y, Schweiger M, et al.
Pharmacol Res Perspect
. 2020 Mar;
8(2):e00573.
PMID: 32125783
A phage-derived human monoclonal antibody against VEGF-C was developed as a potential anti-tumor therapeutic and exhibited fast clearance in preclinical species, with notably faster clearance in serum than in plasma....
6.
Boswell C, Bumbaca Yadav D, Mundo E, Yu S, Lacap J, Fourie-ODonohue A, et al.
Oncotarget
. 2019 Nov;
10(58):6234-6244.
PMID: 31692898
TENB2, a transmembrane proteoglycan protein, is a promising target for antibody drug conjugate (ADC) therapy due to overexpression in human prostate tumors and rapid internalization. We previously characterized how predosing...
7.
Li D, Lee D, Dere R, Zheng B, Yu S, Fuh F, et al.
Br J Pharmacol
. 2019 Jul;
176(19):3805-3818.
PMID: 31270798
Background And Purpose: Polatuzumab vedotin is an antibody-drug conjugate (ADC) being developed for non-Hodgkin's lymphoma. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), an...
8.
Li G, Guo J, Shen B, Bumbaca Yadav D, Sliwkowski M, Crocker L, et al.
Mol Cancer Ther
. 2018 Apr;
17(7):1441-1453.
PMID: 29695635
The receptor tyrosine kinase HER2 is overexpressed in approximately 20% of breast cancer, and its amplification is associated with reduced survival. Trastuzumab emtansine (Kadcyla, T-DM1), an antibody-drug conjugate that is...
9.
Bown H, Bonn C, Yohe S, Bumbaca Yadav D, Patapoff T, Daugherty A, et al.
J Control Release
. 2018 Jan;
273:13-20.
PMID: 29355621
Monoclonal antibodies (mAbs), which are now more frequently administered by subcutaneous (SC) injection rather than intravenously, have become a tremendously successful drug format across a wide range of therapeutic areas....
10.
Hosseini I, Gajjala A, Bumbaca Yadav D, Sukumaran S, Ramanujan S, Paxson R, et al.
J Pharmacokinet Pharmacodyn
. 2018 Jan;
45(2):259-275.
PMID: 29302838
Modeling and simulation (M&S) is increasingly used in drug development to characterize pharmacokinetic-pharmacodynamic (PKPD) relationships and support various efforts such as target feasibility assessment, molecule selection, human PK projection, and...